Recurrent implantation failure: what is established, what is controversial, and why the add-on menu gets dangerous

Few IVF labels create more anxiety or more expensive add-ons than recurrent implantation failure (RIF).

Why three failed transfers are not the same event for everyone

Three untested embryos at advanced maternal age and three euploid blastocysts in a younger patient do not carry the same prior implantation probability.

Start with embryo factors

Age, embryo stage, morphology, genetic-testing context, laboratory performance, and transfer history matter.

Then review uterine factors

Depending on history, evaluation can include cavity anatomy, hydrosalpinx, fibroids/polyps, adhesions, adenomyosis, endometriosis, chronic endometritis, lining development, and transfer technique.

The add-on trap

ESHRE categorizes many tests/treatments as not recommended or only conditionally considered because evidence is absent or inconsistent.

Receptivity tests

Personalized timing assays have been heavily marketed, but routine benefit is not established broadly.

Immune therapies

Intralipids, IVIG, steroids, NK-cell testing, and similar interventions can sound mechanistically plausible without proven routine live-birth benefit.

Disciplined workup

1. Reconstruct prior transfers.
2. Estimate embryo competence.
3. Review uterine/tubal factors.
4. Review transfer technique/preparation.
5. Investigate targeted conditions suggested by history.
6. Discuss uncertain add-ons with explicit limits.

Questions before an add-on

• What diagnosis are we treating?
• What randomized evidence shows improved live birth?
• Would a positive test change management?
• What are harms and opportunity costs?

FAQ

Repeated failure deserves investigation — not an automatic shopping cart of add-ons.

The arithmetic of chance matters

Even an embryo with a high individual implantation probability can fail by chance. Repeated failure becomes more surprising as expected implantation probability rises, which is why euploid status, maternal age, embryo stage, and transfer count belong in the definition discussion.

Hydrosalpinx and structural problems are different from add-ons

Some causes of implantation failure have established treatment pathways. A hydrosalpinx, major intracavitary lesion, or clear transfer problem is not in the same evidence category as speculative immune therapy. A disciplined workup separates actionable pathology from unproven enhancement.

Why “everything normal” does not prove a hidden diagnosis

After a normal workup, clinics and patients can become vulnerable to tests that promise to reveal the invisible cause. A negative standard evaluation may simply mean no treatable cause has been identified yet, not that an immune or microbiome abnormality must exist.

When changing clinics may be reasonable

If repeated transfers involve unclear embryo-lab reporting, inconsistent transfer technique, weak quality systems, or poor communication, reviewing laboratory and procedural quality can be as important as ordering another blood test.

How to use this information in a real IVF consultation

Bring the numbers from your own cycle and ask the clinician to interpret the pattern rather than discussing the topic abstractly. IVF decisions become much clearer when the conversation moves from “What does this test mean?” to “What did this test and my last cycle together teach us about the next cycle?”

Ask what would actually change because of the finding: protocol, dose, trigger, fertilization method, culture strategy, transfer timing, genetic counseling, or nothing. If a test or label does not change management, understand why it is being ordered.

Keep the treatment funnel visible

Egg count, maturity, fertilization, blastocyst formation, genetic status, transfer, implantation, and live birth are different checkpoints. A strong result at one checkpoint improves opportunity but never guarantees success at the next. Good counseling keeps those denominators separate.

What this result should not be allowed to do

One laboratory value, one embryo label, or one disappointing cycle should not collapse the entire treatment conversation into a single verdict. Fertility treatment is probabilistic. The value of a result is in how it changes the next decision, not in how dramatic the number sounds on a portal screen.

Ask the clinic to separate three things explicitly: what is known from your data, what is inferred from population averages, and what remains uncertain. That distinction is especially important when a recommendation carries additional cost, another invasive procedure, embryo-disposition consequences, or an unproven add-on.

What a good second opinion should review

• The raw cycle numbers rather than only the final outcome
• Medication doses and stimulation timeline
• Trigger type and timing where relevant
• Egg maturity and fertilization counts
• Day-by-day embryo development
• Genetic-testing reports where applicable
• Transfer preparation and procedure notes
• Prior uterine/sperm evaluation that could change management

A second opinion is most useful when the new clinician can see the same underlying data as the first clinic. Otherwise you are comparing interpretations built from different information.

How to compare clinics on this topic

Ask how the program tracks its own outcomes for patients with a similar age, diagnosis, and cycle pattern. A good laboratory or fertility program should be able to explain its process without pretending that one protocol, grading system, or add-on works for everyone. Specificity is more useful than superlatives.

Decision checkpoint before the next cycle

Before another stimulation, retrieval, biopsy, or transfer begins, write down the one or two decisions this information is supposed to change. Examples include changing starting dose, changing trigger strategy, choosing conventional insemination versus ICSI, altering culture strategy, choosing a different FET preparation, seeking genetics counseling, or deciding that no change is justified. This prevents retrospective data from becoming expensive trivia.

Then ask what result would make the clinic reverse course. A treatment plan is more credible when the clinician can describe both the reason to use it and the finding that would make them stop using it.

Keep cumulative outcomes separate from per-step percentages

Fertility statistics are easy to make sound better by changing denominators. Fertilization rate is per mature oocyte, blastocyst rate can be reported per fertilized egg or per embryo still in culture, implantation is per transfer, and live birth can be per transfer, per retrieval, or cumulative across a complete egg cohort. When a clinic gives you a percentage, ask for the denominator.

For patients planning more than one retrieval or more than one frozen transfer, cumulative chance across the entire cohort can be more meaningful than the best-looking single-transfer statistic. That is also why avoiding unnecessary embryo discard, unnecessary cycle cancellation, and unsupported add-ons can matter to the overall strategy.